{"generic":"Guanabenz Acetate","drugs":["Guanabenz Acetate","Wytensin"],"mono":{"0":{"id":"265170-s-0","title":"Generic Names","mono":"Guanabenz Acetate"},"1":{"id":"265170-s-1","title":"Dosing and Indications","sub":[{"id":"265170-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hypertension:<\/b> initial, 4 mg ORALLY twice daily<\/li><li><b>Hypertension:<\/b> titrate to maintenance, may increase in increments of 4-8 mg\/day ORALLY at 1-2 wk intervals<\/li><li><b>Hypertension:<\/b> MAX 32 mg ORALLY twice daily<\/li><\/ul>"},{"id":"265170-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness have not been established in children,"},{"id":"265170-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>liver disease:<\/b> dosage adjustments may be required (specific guidelines unavailable)<\/li><li><b>withdrawal schedule:<\/b> patients receiving 48 mg\/day or greater should be tapered off over a 7- to 10-day period<\/li><\/ul>"},{"id":"265170-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hypertension<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Hypertension, Perioperative; Prophylaxis<\/li><li>Left ventricular hypertrophy<\/li><\/ul>"}]},"3":{"id":"265170-s-3","title":"Contraindications\/Warnings","sub":[{"id":"265170-s-3-9","title":"Contraindications","mono":"hypersensitivity to guanabenz products<br\/>"},{"id":"265170-s-3-10","title":"Precautions","mono":"<ul><li>avoid abrupt withdrawal (rebound hypertension)<\/li><li>cerebrovascular disease<\/li><li>liver disease<\/li><li>myocardial infarction (recent)<\/li><li>renal impairment<\/li><li>sedation<\/li><li>severe coronary insufficiency<\/li><\/ul>"},{"id":"265170-s-3-11","title":"Pregnancy Category","mono":"Guanabenz: C (FDA)<br\/>"},{"id":"265170-s-3-12","title":"Breast Feeding","mono":"Guanabenz: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"265170-s-4","title":"Drug Interactions","sub":{"2":{"id":"265170-s-4-15","title":"Moderate","mono":"<ul>Yohimbine (probable)<\/ul>"}}},"5":{"id":"265170-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (3% or less), Edema (3% or less)<\/li><li><b>Gastrointestinal:<\/b>Xerostomia (12% to 37%)<\/li><li><b>Neurologic:<\/b>Asthenia (4% to 10%), Sedated (20% to 50%), Somnolence (20%-50%)<\/li><\/ul><b>Serious<\/b><br\/><b>Cardiovascular:<\/b>Cardiac dysrhythmia (3% or less)<br\/>"},"6":{"id":"265170-s-6","title":"Drug Name Info","sub":{"0":{"id":"265170-s-6-17","title":"US Trade Names","mono":"Wytensin<br\/>"},"2":{"id":"265170-s-6-19","title":"Class","mono":"<ul><li>Alpha-2 Adrenergic Agonist<\/li><li>Antihypertensive<\/li><\/ul>"},"3":{"id":"265170-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"265170-s-7","title":"Mechanism Of Action","mono":"Guanabenz acetate is an antihypertensive agent and a derivative of aminoguanidine. Its antihypertensive effect is mediated by the stimulation of the centrally active alpha adrenergic receptors which results in a decreased sympathetic outflow at the bulbar level to the peripheral circulatory system from the brain.<br\/>"},"8":{"id":"265170-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"265170-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 2 h to 5 h<\/li><li>Bioavailability: 75%<\/li><li>Effect of food: none<\/li><\/ul>"},"3":{"id":"265170-s-8-26","title":"Excretion","mono":"Renal: less than 1% unchanged <br\/>"},"4":{"id":"265170-s-8-27","title":"Elimination Half Life","mono":"<ul><li>6 h<\/li><li>Renal impairment: prolonged<\/li><\/ul>"}}},"10":{"id":"265170-s-10","title":"Monitoring","mono":"blood pressure<br\/>"},"12":{"id":"265170-s-12","title":"Toxicology","sub":[{"id":"265170-s-12-31","title":"Clinical Effects","mono":"<b>GUANABENZ<\/b><br\/>OVERDOSE: similar to clonidine: hypotension, bradycardia, respiratory depression, somnolence, and miosis.  Transient early hypertension. WITHDRAWAL: Diaphoresis, nervousness, palpitations, insomnia, malaise, abdominal cramps, and elevated diastolic BP 16 to 48 hours after abrupt withdrawal. <br\/>"},{"id":"265170-s-12-32","title":"Treatment","mono":"<b>GUANABENZ <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine.<\/li><li>Naloxone: Inconclusive, may treat hypotension, apnea, CNS depression. DOSE - Adult\/Child 2 mg IV. Repeat as needed.<\/li><li>Bradycardia: Atropine. Adult 0.5 to 1 mg; Pediatric 0.02 mg\/kg; repeat in 3-5 min. MAXIUM DOSE - Adult 2 mg, Child 0.5 mg IV.<\/li><li>Monitoring of patient: ECG, vital signs, pulse oximetry.<\/li><li>Hypertensive episode: Usually transient; do not treat unless end organ effects present. Nitroprusside 0.5 mcg\/kg\/min titrate to effect.<\/li><\/ul>"},{"id":"265170-s-12-33","title":"Range of Toxicity","mono":"<b>GUANABENZ<\/b><br\/>Data limited.  Hypotension and bradycardia reported after 160 to 320 mg in adults, 4 mg in a child. <br\/>"}]},"13":{"id":"265170-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause somnolence.<\/li><li>This drug may cause xerostomia or anxiety.<\/li><li>Advise patient against sudden discontinuation of drug, as this may precipitate rebound hypertension.<\/li><li>Patient should avoid drinking alcohol during therapy.<\/li><\/ul>"}}}